{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:42:34Z","timestamp":1792672954748,"version":"4.5.0"},"reference-count":2,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"DOI":"10.1177\/13524585261496131","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:56:12Z","timestamp":1792385772000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Author response\u2014Rituximab versus ocrelizumab: When inference exceeds the evidence"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1174","authenticated-orcid":false,"given":"Nathan Y.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie I.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice J.","family":"Schabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Chu NY Roberts JI Hunt DJ et al. Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia Canada. Mult Scler. Epub ahead of print 3 July 2026. https:\/\/doi.org\/10.1177\/13524585261453817","DOI":"10.1177\/13524585261453817"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Torkildsen \u00d8 Brustad HK H\u00f8gest\u00f8l EA et al. Rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. N Engl J Med 2026; 395: 44\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2600993","DOI":"10.1056\/NEJMoa2600993"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261496131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261496131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261496131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:47:52Z","timestamp":1792669672000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261496131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":2,"alternative-id":["10.1177\/13524585261496131"],"URL":"https:\/\/doi.org\/10.1177\/13524585261496131","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"article-number":"13524585261496131"}}